# PDE4B

## Overview
Phosphodiesterase 4B (PDE4B) is a gene that encodes the enzyme phosphodiesterase 4B, which is a member of the phosphodiesterase family of proteins. This enzyme plays a pivotal role in cellular signaling by regulating the intracellular levels of cyclic adenosine monophosphate (cAMP) through its hydrolysis to AMP. PDE4B is categorized as a phosphodiesterase enzyme and is involved in various physiological processes, including immune and inflammatory responses, as well as neuronal signaling. The gene is expressed in multiple isoforms due to alternative splicing, each with distinct regulatory roles in different tissues. Notably, PDE4B is implicated in psychiatric disorders and certain cancers, making it a significant target for therapeutic research (Fatemi2008PDE4B; Hsien2020PDE4; Azam2014Selective).

## Structure
The PDE4B gene encodes the phosphodiesterase 4B enzyme, which is involved in the hydrolysis of cyclic AMP (cAMP) and plays a crucial role in cellular signaling. The primary structure of PDE4B consists of a sequence of amino acids that form various isoforms due to alternative splicing, including PDE4B1, PDE4B2, PDE4B3, and the novel PDE4B4. The PDE4B4 isoform is characterized by a unique N-terminal region of 16 amino acids, which distinguishes it from other PDE4B isoforms (SHEPHERD2003Molecular).

The secondary structure of PDE4B includes alpha helices, as seen in the catalytic domain of PDE4B2B, which is composed of 17 alpha helices forming three subdomains (Xu2000Atomic). The tertiary structure features a catalytic domain with a conserved fold typical of phosphodiesterases, including a binuclear metal ion motif crucial for its enzymatic function (Xu2000Atomic). This domain contains conserved residues that interact with cAMP, contributing to the enzyme's specificity and function.

PDE4B can undergo post-translational modifications such as phosphorylation, which can affect its activity. For instance, PDE4B4 is phosphorylated and activated by protein kinase A (PKA) (SHEPHERD2003Molecular). The quaternary structure may involve interactions with other proteins, although specific details are not provided in the context.

## Function
Phosphodiesterase 4B (PDE4B) is a critical enzyme involved in the regulation of intracellular cyclic adenosine monophosphate (cAMP) levels by catalyzing its hydrolysis to AMP. This regulation is essential for modulating various cellular processes, particularly in immune and inflammatory responses. PDE4B is predominantly expressed in monocytes and neutrophils, where it plays a central role in inflammation (Azam2014Selective). It is selectively induced by lipopolysaccharide (LPS) in monocytes and macrophages, and its activity is necessary for the full tumor necrosis factor-alpha (TNF-α) response, highlighting its importance in immune signaling (Jin2002Induction).

In the context of B lymphocytes, PDE4B, particularly the splice variant PDE4B2, is involved in regulating B cell proliferation by modulating cAMP levels and protein kinase A (PKA) activity. Inhibition of PDE4B leads to increased cAMP levels, which enhances B cell proliferation (Gantner1998Phosphodiesterase). PDE4B is also expressed in the locus coeruleus, a brain region involved in stress-related processes, indicating its role in neuronal signaling and potential implications in mood regulation (Azam2014Selective). Overall, PDE4B's regulation of cAMP levels is crucial for maintaining cellular homeostasis and responding to inflammatory stimuli.

## Clinical Significance
Mutations and alterations in the expression of the PDE4B gene have been implicated in several psychiatric and hematologic conditions. In schizophrenia, decreased expression of PDE4B isoforms has been observed in the brains of affected individuals, suggesting a potential link between PDE4B dysregulation and the disorder. Specific single nucleotide polymorphisms (SNPs) within the PDE4B gene are associated with schizophrenia, particularly in Caucasian and African American populations, indicating that genetic variations may contribute to the disease's pathophysiology (Fatemi2008PDE4B).

In diffuse large B-cell lymphoma (DLBCL), PDE4B is overexpressed, which may confer resistance to cAMP-induced apoptosis, contributing to poor outcomes. This overexpression is associated with the inhibition of the PI3K/AKT pathway, suggesting that PDE4B plays a role in modulating apoptosis in these tumors (Smith2005The). PDE4B is also implicated in other cancers, such as colorectal and non-small cell lung cancer, where its expression is linked to oncogenic pathways and tumor progression (Hsien2020PDE4).

In psychiatric conditions, a specific mutation, PDE4B Y358C, results in decreased cAMP hydrolysis, affecting memory and anxiety regulation. This mutation alters interactions with DISC1, a protein associated with mental illness, suggesting that PDE4B inhibition could be a therapeutic approach for anxiety and cognitive disorders (McGirr2015Specific).

## Interactions
PDE4B interacts with several proteins, playing a significant role in brain signaling and psychiatric disorders. It forms complexes with the Disrupted-in-schizophrenia 1 (DISC1) protein, which is implicated in schizophrenia and other mental illnesses. This interaction is particularly notable with the PDE4B1 isoform, which remains associated with DISC1 even when intracellular cAMP levels are elevated, unlike other PDE4 isoforms such as PDE4D3 (Murdoch2007IsoformSelective). The interaction involves specific binding sites on DISC1, including additional PDE4B-specific sites that contribute to the stability of the complex (Murdoch2007IsoformSelective).

PDE4B is also part of a multiprotein complex that includes NDE1, NDEL1, LIS1, and dynein, which are involved in neuronal migration and signal transduction. This complex is found at the centrosome and synapses, where it may modulate synaptic signaling mechanisms (Bradshaw2008DISC1). The interaction with DISC1 and other proteins is regulated by cAMP levels through PKA-mediated processes, affecting neuronal production and positioning, which may contribute to psychiatric disorders (Tibbo2020Phosphodiesterase). These interactions highlight PDE4B's role as a potential therapeutic target for psychiatric and inflammatory conditions (Tibbo2020Phosphodiesterase).


## References


[1. (Fatemi2008PDE4B) S. Hossein Fatemi, David P. King, Teri J. Reutiman, Timothy D. Folsom, Jessica A. Laurence, Susanne Lee, Yu-Ti Fan, Sara A. Paciga, Marco Conti, and Frank S. Menniti. Pde4b polymorphisms and decreased pde4b expression are associated with schizophrenia. Schizophrenia Research, 101(1–3):36–49, April 2008. URL: http://dx.doi.org/10.1016/j.schres.2008.01.029, doi:10.1016/j.schres.2008.01.029. This article has 111 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.schres.2008.01.029)

[2. (Bradshaw2008DISC1) Nicholas J. Bradshaw, Fumiaki Ogawa, Beatriz Antolin-Fontes, Jennifer E. Chubb, Becky C. Carlyle, Sheila Christie, Antoine Claessens, David J. Porteous, and J. Kirsty Millar. Disc1, pde4b, and nde1 at the centrosome and synapse. Biochemical and Biophysical Research Communications, 377(4):1091–1096, December 2008. URL: http://dx.doi.org/10.1016/j.bbrc.2008.10.120, doi:10.1016/j.bbrc.2008.10.120. This article has 70 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2008.10.120)

[3. (Smith2005The) Peter G. Smith, Fengfei Wang, Kathryn N. Wilkinson, Kerry J. Savage, Ulf Klein, Donna S. Neuberg, Gideon Bollag, Margaret A. Shipp, and Ricardo C. T. Aguiar. The phosphodiesterase pde4b limits camp-associated pi3k/akt–dependent apoptosis in diffuse large b-cell lymphoma. Blood, 105(1):308–316, January 2005. URL: http://dx.doi.org/10.1182/blood-2004-01-0240, doi:10.1182/blood-2004-01-0240. This article has 114 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2004-01-0240)

[4. (Tibbo2020Phosphodiesterase) Amy J. Tibbo and George S. Baillie. Phosphodiesterase 4b: master regulator of brain signaling. Cells, 9(5):1254, May 2020. URL: http://dx.doi.org/10.3390/cells9051254, doi:10.3390/cells9051254. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells9051254)

[5. (Xu2000Atomic) Robert X. Xu, Anne M. Hassell, Dana Vanderwall, Millard H. Lambert, William D. Holmes, Michael A. Luther, Warren J. Rocque, Michael V. Milburn, Yingdong Zhao, Hengming Ke, and Robert T. Nolte. Atomic structure of pde4: insights into phosphodiesterase mechanism and specificity. Science, 288(5472):1822–1825, June 2000. URL: http://dx.doi.org/10.1126/science.288.5472.1822, doi:10.1126/science.288.5472.1822. This article has 286 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.288.5472.1822)

[6. (SHEPHERD2003Molecular) Malcolm SHEPHERD, Theresa McSORLEY, Aileen E. OLSEN, Lee Ann JOHNSTON, Neil C. THOMSON, George S. BAILLIE, Miles D. HOUSLAY, and Graeme B. BOLGER. Molecular cloning and subcellular distribution of the novel pde4b4 camp-specific phosphodiesterase isoform. Biochemical Journal, 370(2):429–438, March 2003. URL: http://dx.doi.org/10.1042/bj20021082, doi:10.1042/bj20021082. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20021082)

[7. (McGirr2015Specific) Alexander McGirr, Tatiana V Lipina, Ho-Suk Mun, John Georgiou, Ahmed H Al-Amri, Enoch Ng, Dongxu Zhai, Christina Elliott, Ryan T Cameron, Jonathan GL Mullins, Fang Liu, George S Baillie, Steven J Clapcote, and John C Roder. Specific inhibition of phosphodiesterase-4b results in anxiolysis and facilitates memory acquisition. Neuropsychopharmacology, 41(4):1080–1092, August 2015. URL: http://dx.doi.org/10.1038/npp.2015.240, doi:10.1038/npp.2015.240. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/npp.2015.240)

[8. (Azam2014Selective) Mohammed Afzal Azam. Selective phosphodiesterase 4b inhibitors: a review. Scientia Pharmaceutica, 82(3):453–481, 2014. URL: http://dx.doi.org/10.3797/scipharm.1404-08, doi:10.3797/scipharm.1404-08. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.3797/scipharm.1404-08)

[9. (Jin2002Induction) S.-L. Catherine Jin and Marco Conti. Induction of the cyclic nucleotide phosphodiesterase pde4b is essential for lps-activated tnf-α responses. Proceedings of the National Academy of Sciences, 99(11):7628–7633, May 2002. URL: http://dx.doi.org/10.1073/pnas.122041599, doi:10.1073/pnas.122041599. This article has 292 citations.](https://doi.org/10.1073/pnas.122041599)

[10. (Murdoch2007IsoformSelective) Hannah Murdoch, Shaun Mackie, Daniel M. Collins, Elaine V. Hill, Graeme B. Bolger, Enno Klussmann, David J. Porteous, J. Kirsty Millar, and Miles D. Houslay. Isoform-selective susceptibility of disc1/phosphodiesterase-4 complexes to dissociation by elevated intracellular camp levels. The Journal of Neuroscience, 27(35):9513–9524, August 2007. URL: http://dx.doi.org/10.1523/jneurosci.1493-07.2007, doi:10.1523/jneurosci.1493-07.2007. This article has 133 citations.](https://doi.org/10.1523/jneurosci.1493-07.2007)

[11. (Hsien2020PDE4) Samuel Hsien Lai, Guston Zervoudakis, Jesse Chou, Mark E. Gurney, and Kelly M. Quesnelle. Pde4 subtypes in cancer. Oncogene, 39(19):3791–3802, March 2020. URL: http://dx.doi.org/10.1038/s41388-020-1258-8, doi:10.1038/s41388-020-1258-8. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-020-1258-8)

[12. (Gantner1998Phosphodiesterase) Florian Gantner, Christine Götz, Volker Gekeler, Christian Schudt, Albrecht Wendel, and Armin Hatzelmann. Phosphodiesterase profile of human b lymphocytes from normal and atopic donors and the effects of pde inhibition on b cell proliferation. British Journal of Pharmacology, 123(6):1031–1038, March 1998. URL: http://dx.doi.org/10.1038/sj.bjp.0701688, doi:10.1038/sj.bjp.0701688. This article has 65 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/sj.bjp.0701688)